Actinium Pharmaceuticals Inc - Company Profile
Powered by 
All the sales intelligence you need on Actinium Pharmaceuticals Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Actinium Pharmaceuticals Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Actinium Pharmaceuticals Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Actinium Pharmaceuticals Inc (Actinium Pharmaceuticals) is a biopharmaceutical company that develops product candidates for cancer treatments by using Actinium-225 technology. The company’s lead product ATNM-400 for the treatment of prostate cancer, non-small cell lung cancer (NSCLC) and breast cancer. Its proprietary Antibody Warhead Enabling (AWE) technology platform is used to produce antibody radiation conjugates (ARC), a highly potent and selective form of targeted radiotherapy. The company therapeutic areas include oncology, hematology and gene therapies. It colloborates with pharma companies. Actinium Pharmaceuticals is headquartered in New York, the US.
Headquarters
United States of America
Address
23rd Floor, 100 Park Avenue, New York City, 10017
Website
www.actiniumpharma.com
No of Employees
25
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ATNM (AFM)
Revenue (2024)
$90,000
EPS
XYZ
Net Income (2024)
XYZ
11.4%
(2024 vs 2023)
Market Cap*
$28.9M
Net Profit Margin (2024)
XYZ
-1,074.6%
(2024 vs 2023)
* As of and is in US$
Actinium Pharmaceuticals Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| ATNM-400: |
| Prostate Cancer |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | Actinium Pharmaceuticals Inc | Novartis AG | Telix Pharmaceuticals Ltd | Point Biopharma Global Inc | Gyre Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Switzerland | Australia | United States of America | United States of America |
| City | New York City | Basel | Melbourne | Indianapolis | San Diego |
| State/Province | New York | Basel-Stadt | Victoria | Indiana | California |
| No. of Employees | 25 | 75,267 | 1,120 | 129 | 618 |
| Entity Type | Public | Public | Public | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Sandesh Seth | Chairman; Chief Executive Officer | Executive Board | 2017 | 61 |
| Steve O Loughlin | Chief Financial Officer; Director; Secretary | Executive Board | 2020 | 41 |
| Steffen Heeger, MD, MSc | Chief Medical Officer | Senior Management | 2026 | - |
| Paul Diamond, Ph.D. | Vice President - Legal and Intellectual Property Counsel | Senior Management | 2021 | - |
| Madhuri Vusirikala, M.D. | Vice President - Clinical Development BMT and Cellular Therapy | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer